Guideline Recommendations vs Real-World Experience in Treating Patients With EGFR-Mutant NSCLC

Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity management, and individual patient complexities. Although evidence-based protocols provide structure, clinicians frequently adapt treatment plans to accommodate nuanced scenarios like comorbidities or organ-specific metastases.

They point out that co-alterations such as TP53 mutations and liver metastases introduce additional risk, often correlating with poorer outcomes and influencing first-line selection. The subgroup analyses from MARIPOSA and FLAURA-2 provide valuable insight into these high-risk populations, guiding clinicians toward more aggressive or combination-based approaches.

Experience-based adaptation of guidelines allows for tailored care without compromising evidence-based rigor. Panelists stress the importance of integrating both structured recommendations and clinical intuition to achieve optimal patient outcomes.